Edited by Peter Hillerberg1 min readStories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
UBS analyst Joshua Spector trimmed targets across chemicals on Tuesday. Air Products and Chemicals saw its price target cut to $305 from $336, while Albemarle dropped to $150 from $175. Both names kept their existing ratings intact.
The Albemarle cut stands out. Short interest sits at 9.6% of free float, one of the higher readings in the materials space. The lithium producer has faced prolonged pressure from weak lithium prices. UBS's lower target suggests little near-term relief is expected.
Citigroup's Joanne Wuensch swept through medtech with mixed signals. Boston Scientific and GE HealthCare Technologies both had targets trimmed. Johnson and Johnson bucked that trend. Citi raised its J&J target to $303 and reiterated Buy. Medicare Advantage penetration reached 51.1% in June 2026, the highest on record since 2013, and enrolment hit 36.1 million. That steady structural growth in managed care keeps medtech demand durable.
Elsewhere, Citigroup raised targets on custody banks State Street and Northern Trust, citing improving fee income prospects heading into year-end.
PTC Inc. saw multiple analyst changes, with the consensus target edging up to $177 from $174.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
